Avadomide

An investigational drug for cancer treatment

Avadomide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Avadomide is an investigational drug that is being studied for its potential use in the treatment of various types of cancer. It belongs to a class of drugs known as immunomodulatory drugs (IMiDs), which are designed to modulate the immune system to enhance the body's ability to fight cancer.

Mechanism of Action

Avadomide works by modulating the activity of the cereblon protein, which is a component of the ubiquitin ligase complex. This modulation leads to the degradation of specific proteins that are involved in the proliferation and survival of cancer cells. By targeting these proteins, avadomide can induce apoptosis in cancer cells and inhibit their growth.

Clinical Development

Avadomide is currently undergoing clinical trials to evaluate its efficacy and safety in treating various hematological malignancies, including multiple myeloma and non-Hodgkin lymphoma. These trials are designed to assess the drug's ability to improve patient outcomes when used alone or in combination with other therapies.

Potential Benefits

The potential benefits of avadomide include its ability to selectively target cancer cells while sparing normal cells, which may result in fewer side effects compared to traditional chemotherapy. Additionally, as an oral medication, avadomide offers a convenient administration route for patients.

Side Effects

As with many investigational drugs, avadomide may cause side effects. Commonly reported side effects in clinical trials include fatigue, nausea, and anemia. The safety profile of avadomide continues to be evaluated in ongoing studies.

Research and Future Directions

Research on avadomide is focused on understanding its full potential in cancer therapy, including its use in combination with other treatments such as monoclonal antibodies and checkpoint inhibitors. Future studies may explore its application in other types of cancer and its long-term effects on patient survival and quality of life.

Related Pages

• Immunomodulatory drugs
• Cereblon
• Multiple myeloma
• Non-Hodgkin lymphoma